FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154240260> ?p ?o ?g. }

• W2154240260 endingPage "57" @default.
• W2154240260 startingPage "51" @default.
• W2154240260 abstract "Insulin-like growth factor 1 (IGF-1) is an important growth and anti-apoptotic factor for the cancer cells in several malignancies and in multiple myeloma recent studies support the hypothesis of a role for IGF-1 in disease progression; however, clinico-biological relevance of IGF-1 was never studied in B-cell chronic lymphocytic leukemia (CLL).Using a quantitative sandwich immunoassay technique (ELISA) (Quantikine, Human IGF-1 and IGFBP-3, R&D Systems), we measured the concentration of IGF-1 and its major binding protein IGF-binding protein 3 (IGFBP-3) in serum drawn at the time of diagnosis from 77 Binet stage A CLL patients.Either IGF-1 or IGFBP-3 were significantly decreased compared with healthy age- and sex-matched controls (P < 0.0001 for both; Mann-Whitney test). Serum levels of IGF-1 and IGFBP-3 paralleled each other (P = 0.002); in contrast, no significant correlation was found between serum levels of IGF-1 and clinico-hematological variables including age (P = 0.253), sex (P = 0.270), Rai clinical substages (P = 0.140), lactate dehydrogenase (P = 0.956), beta2-microglobulin (P = 0.368), lymphocyte count (P = 0.703) and lymphocyte doubling time (LDT, P = 0.233). When correlation were attempted with circulating levels of angiogenic cytokines such as vascular endothelial growth factor (P = 0.971), basic fibroblastic growth factor (P = 0.695), angiogenin (P = 0.282) or adhesion molecules such as vascular cell adhesion molecule-1 (P = 0.318), intercellular adhesion molecule-1 (P = 0.883) and platelet endothelial cell adhesion molecule-1 (P = 0.772) similar results were found. Serum levels of IGF-1 were further evaluated as a dichotomous variable with respect to progression-free survival (PFS), an endpoint surrogate for overall survival in early B-cell CLL. The best separation of curves was seen with the cutoff point at the 75th percentile of IGF-1 levels (i.e., 93 pg/mL). Median PFS was 63 months in the patient group with low IGF-1, compared with a median PFS of 40 months in the remaining patients (P = 0.03). In the multivariate analysis performed including variables significant at univariate analysis [i.e. Rai substage (P = 0.002); LDT (P = 0.004), IGF-1 (P = 0.01)], only Rai substage retained prognostic significance (P = 0.006). However, after removing from analysis LDT (only six of 77 had an LDT < 12 months), either IGF-1 or Rai substage entered the model at a significant level (P = 0.03 and P = 0.01, respectively).IGF-1 did not correlate with markers of tumor burden or clinical status in CLL thus suggesting that levels of this cytokine do not reflect the intrinsic malignancy of disease. Results of the present study highlight, however, its involvement in mechanisms of disease progression in early CLL." @default.
• W2154240260 created "2016-06-24" @default.
• W2154240260 creator A5006569608 @default.
• W2154240260 creator A5009980841 @default.
• W2154240260 creator A5012195468 @default.
• W2154240260 creator A5040783792 @default.
• W2154240260 creator A5054370212 @default.
• W2154240260 creator A5061896020 @default.
• W2154240260 creator A5062047451 @default.
• W2154240260 creator A5086743021 @default.
• W2154240260 date "2005-10-27" @default.
• W2154240260 modified "2023-10-16" @default.
• W2154240260 title "Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression" @default.
• W2154240260 cites W1243376384 @default.
• W2154240260 cites W1429374962 @default.
• W2154240260 cites W1484886449 @default.
• W2154240260 cites W1526220366 @default.
• W2154240260 cites W154103547 @default.
• W2154240260 cites W1565618380 @default.
• W2154240260 cites W1965851569 @default.
• W2154240260 cites W1988509506 @default.
• W2154240260 cites W1988605844 @default.
• W2154240260 cites W1996832816 @default.
• W2154240260 cites W1997358750 @default.
• W2154240260 cites W2013187395 @default.
• W2154240260 cites W2020636054 @default.
• W2154240260 cites W2027092131 @default.
• W2154240260 cites W2027662401 @default.
• W2154240260 cites W2031192472 @default.
• W2154240260 cites W2052799208 @default.
• W2154240260 cites W2078447501 @default.
• W2154240260 cites W2082253535 @default.
• W2154240260 cites W2084991537 @default.
• W2154240260 cites W2086637735 @default.
• W2154240260 cites W2093014461 @default.
• W2154240260 cites W2102552995 @default.
• W2154240260 cites W2111843196 @default.
• W2154240260 cites W2117350664 @default.
• W2154240260 cites W2156131696 @default.
• W2154240260 cites W2157109399 @default.
• W2154240260 cites W2208911945 @default.
• W2154240260 cites W2318796295 @default.
• W2154240260 cites W2318933236 @default.
• W2154240260 cites W2407514301 @default.
• W2154240260 cites W2991466891 @default.
• W2154240260 cites W343303420 @default.
• W2154240260 cites W60865865 @default.
• W2154240260 doi "https://doi.org/10.1111/j.1600-0609.2005.00553.x" @default.
• W2154240260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16343271" @default.
• W2154240260 hasPublicationYear "2005" @default.
• W2154240260 type Work @default.
• W2154240260 sameAs 2154240260 @default.
• W2154240260 citedByCount "11" @default.
• W2154240260 countsByYear W21542402602012 @default.
• W2154240260 countsByYear W21542402602013 @default.
• W2154240260 countsByYear W21542402602016 @default.
• W2154240260 countsByYear W21542402602018 @default.
• W2154240260 countsByYear W21542402602020 @default.
• W2154240260 crossrefType "journal-article" @default.
• W2154240260 hasAuthorship W2154240260A5006569608 @default.
• W2154240260 hasAuthorship W2154240260A5009980841 @default.
• W2154240260 hasAuthorship W2154240260A5012195468 @default.
• W2154240260 hasAuthorship W2154240260A5040783792 @default.
• W2154240260 hasAuthorship W2154240260A5054370212 @default.
• W2154240260 hasAuthorship W2154240260A5061896020 @default.
• W2154240260 hasAuthorship W2154240260A5062047451 @default.
• W2154240260 hasAuthorship W2154240260A5086743021 @default.
• W2154240260 hasConcept C126322002 @default.
• W2154240260 hasConcept C134018914 @default.
• W2154240260 hasConcept C167734588 @default.
• W2154240260 hasConcept C170493617 @default.
• W2154240260 hasConcept C203014093 @default.
• W2154240260 hasConcept C2775960820 @default.
• W2154240260 hasConcept C2777025900 @default.
• W2154240260 hasConcept C2777761686 @default.
• W2154240260 hasConcept C2777938653 @default.
• W2154240260 hasConcept C2778461978 @default.
• W2154240260 hasConcept C2780689927 @default.
• W2154240260 hasConcept C71924100 @default.
• W2154240260 hasConceptScore W2154240260C126322002 @default.
• W2154240260 hasConceptScore W2154240260C134018914 @default.
• W2154240260 hasConceptScore W2154240260C167734588 @default.
• W2154240260 hasConceptScore W2154240260C170493617 @default.
• W2154240260 hasConceptScore W2154240260C203014093 @default.
• W2154240260 hasConceptScore W2154240260C2775960820 @default.
• W2154240260 hasConceptScore W2154240260C2777025900 @default.
• W2154240260 hasConceptScore W2154240260C2777761686 @default.
• W2154240260 hasConceptScore W2154240260C2777938653 @default.
• W2154240260 hasConceptScore W2154240260C2778461978 @default.
• W2154240260 hasConceptScore W2154240260C2780689927 @default.
• W2154240260 hasConceptScore W2154240260C71924100 @default.
• W2154240260 hasIssue "1" @default.
• W2154240260 hasLocation W21542402601 @default.
• W2154240260 hasLocation W21542402602 @default.
• W2154240260 hasOpenAccess W2154240260 @default.
• W2154240260 hasPrimaryLocation W21542402601 @default.
• W2154240260 hasRelatedWork W2000727265 @default.
• W2154240260 hasRelatedWork W2038000824 @default.

• next